Drug Profile

APG 279

Alternative Names: APG 990 + APG 777; APG-279

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apogee Therapeutics
Class Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Interleukin 13 inhibitors; OX40 ligand inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Atopic dermatitis

Most Recent Events

17 Mar 2025 Apogee Therapeutics announces intention to submit an Investigational New Drug application or foreign equivalent for APG 279 co-formulation for Atopic dermatitis
03 Mar 2025 Preclinical trials in Atopic dermatitis in USA (Parenteral), prior to March 2025
03 Mar 2025 Pharmacodynamics and adverse event data from a preclinical trial in Atopic dermatitis released by Apogee Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com